The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life

Journal of Drugs in Dermatology

Volumn 11, Issue 11, 2012, Pages

  Nardone, Beatrice ^a   Hensley, Jennifer R ^a   Kulik, Laura ^a   West, Dennis P ^a   Mulcahy, Mary ^a   Rademaker, Alfred ^a   Lacouture, Mario E ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORRELATIONAL STUDY; DISEASE SEVERITY; DRUG ERUPTION; EMOTION; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALE; OVARY CANCER; PAIN; PRURITUS; QUALITY OF LIFE; SCORING SYSTEM; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN TOXICITY; SKINDEX 16; STOMATITIS; XEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HAND-FOOT SYNDROME; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84870186697     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53(5):917-930.
2. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther. 2007;29(7):1338-1353. (Pubitemid 47348120)
3. Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev. 2008;34(1):37-48. (Pubitemid 351168610)
4. Cabibbo G, Latteri F, Antonucci M, Craxi A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol. 2009;6(3):159-169.
5. Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and nonrenal cell carcinoma: a meta-analysis. Clin Genitourin Cancer. 2009;7(1):11-19.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med. 2007;356(2):125-134. (Pubitemid 46089673)
7. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007;178(5):1883-1887. (Pubitemid 47538608)
8. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505-2512. (Pubitemid 46630627)
9. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19(11):1955-1961.
10. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007;7(4):127-134.
11. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411-1416.
12. Balkrishnan R, Manuel J, Feldman SR, Rapp SR. Measurement of health-related quality of life (HRQOL) associated with skin disease. J Am Acad Dermatol. 2004;51(1 Suppl):S3-S4.
13. Both H, Essink-Bot ML, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127(12):2726-2739. (Pubitemid 350134835)
14. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181. (Pubitemid 36962641)
15. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0. 2006; 3. Available at: http://ctep.cancer.gov/protocoldevelopment/ electronic-applications/docs/ctcaev3.pdf. Accessed September 2012.
16. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105-110. (Pubitemid 32588315)
17. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903-909. (Pubitemid 44615944)
18. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176-186.
19. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9):1001-1011.
20. Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist. 2009;14(3):291-302.